IV Spanish Consensus Conference on Helicobacter pylori infection treatment.

[1]  D. Graham,et al.  Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. , 2018, Gastroenterology.

[2]  J. Gisbert,et al.  Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double‐blind, placebo‐controlled trial , 2018, Helicobacter.

[3]  You-ming Huang,et al.  Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial , 2018, Scientific Reports.

[4]  T. Tomita,et al.  Systematic review with meta‐analysis: Vonoprazan, a potent acid blocker, is superior to proton‐pump inhibitors for eradication of clarithromycin‐resistant strains of Helicobacter pylori , 2018, Helicobacter.

[5]  J. Sánchez-Delgado,et al.  Systematic review, meta‐analysis, and meta‐regression: Successful second‐line treatment for Helicobacter pylori , 2018, Helicobacter.

[6]  M. Rodríguez-García,et al.  Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice. , 2018, Gastroenterologia y hepatologia.

[7]  E. A. Andrés Esteban,et al.  Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin‐containing regimens , 2018, Helicobacter.

[8]  J. Gisbert,et al.  Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. , 2017, Gastroenterologia y hepatologia.

[9]  Metin Uzman,et al.  Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen , 2017, Medical Principles and Practice.

[10]  Jianhua He,et al.  Probiotics in 14-day triple therapy for Asian pediatric patients with Helicobacter pylori infection: a network meta-analysis , 2017, Oncotarget.

[11]  A. D. Paredes,et al.  Limited effectiveness with a 10‐day bismuth‐containing quadruple therapy (Pylera®) in third‐line recue treatment for Helicobacter pylori infection. A real‐life multicenter study , 2017 .

[12]  I. Bastón-Rey,et al.  High primary antibiotic resistance of Helicobacter Pylori strains isolated from dyspeptic patients: A prevalence cross‐sectional study in Spain , 2017, Helicobacter.

[13]  Tikkam Singh,et al.  Review: A Japanese population‐based meta‐analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? , 2017, Helicobacter.

[14]  Jing Liu,et al.  Probiotics in Helicobacter pylori eradication therapy: Systematic review and network meta-analysis. , 2017, Clinics and research in hepatology and gastroenterology.

[15]  Jing Liu,et al.  Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis , 2017, European Journal of Clinical Pharmacology.

[16]  Mototsugu Kato,et al.  Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin , 2017, Helicobacter.

[17]  Y. Jung,et al.  Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradication , 2017, Alimentary pharmacology & therapeutics.

[18]  J. Gisbert,et al.  Optimization strategies aimed to increase the efficacy of H. pylori eradication therapies , 2017, Helicobacter.

[19]  M. Zhang,et al.  [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of Helicobacter pylori as the rescue therapy: a meta analysis]. , 2017, Zhonghua nei ke za zhi.

[20]  Liya Zhou,et al.  Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection , 2017, Digestive Diseases and Sciences.

[21]  J. Gisbert,et al.  Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis , 2017, Drugs.

[22]  Juntaro Matsuzaki,et al.  Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients , 2017, United European gastroenterology journal.

[23]  F. Bermejo,et al.  IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori , 2016 .

[24]  E. El-Omar,et al.  Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial , 2016, The Lancet.

[25]  M. Kutz,et al.  [10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection]. , 2016, Gastroenterologia y hepatologia.

[26]  Jiaqi Deng,et al.  Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials , 2016, PloS one.

[27]  R. Hunt,et al.  Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report , 2016, Gut.

[28]  L. Marzio,et al.  Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third‐Line Treatment of Helicobacter pylori Infection: Two Pilot Studies , 2016, Helicobacter.

[29]  P. Malfertheiner,et al.  Systematic review and meta-analysis: Multi-strain probiotics as adjunct therapy for Helicobacter pylori eradication and prevention of adverse events , 2016, United European gastroenterology journal.

[30]  J. Gisbert,et al.  Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infection , 2016, Therapeutic advances in gastroenterology.

[31]  R. Hunt,et al.  The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. , 2016, Gastroenterology.

[32]  F. Mégraud,et al.  Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. , 2016, The Cochrane database of systematic reviews.

[33]  Jianzhong Zhang,et al.  Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[34]  Li Yang,et al.  Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review , 2016, American journal of therapeutics.

[35]  Yanqing Li,et al.  Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial , 2016, Helicobacter.

[36]  S. Koletzko,et al.  Sequential Therapy for Helicobacter pylori Infection in Treatment‐naïve Children , 2016, Helicobacter.

[37]  Chao Lu,et al.  Probiotic supplementation does not improve eradication rate of Helicobacter pylori infection compared to placebo based on standard therapy: a meta-analysis , 2016, Scientific Reports.

[38]  Guoxin Zhang,et al.  Tailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication , 2016, Medicine.

[39]  L. Bujanda,et al.  Antimicrobial Susceptibility‐Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance , 2016, Helicobacter.

[40]  P. Apostolopoulos,et al.  Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study , 2016, Scandinavian journal of gastroenterology.

[41]  Deng-Chyang Wu,et al.  Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial. , 2015, World journal of gastroenterology.

[42]  C. Shun,et al.  Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial , 2015, Gut.

[43]  D. Graham,et al.  Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy , 2015, Gut.

[44]  J. Gisbert.  [Helicobacter pylori-associated diseases]. , 2015, Gastroenterologia y hepatologia.

[45]  D. Graham,et al.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. , 2015, Gastroenterology clinics of North America.

[46]  A. Shiotani,et al.  Practical Aspects in Choosing a Helicobacter pylori Therapy. , 2015, Gastroenterology clinics of North America.

[47]  J. Gisbert,et al.  Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. , 2015, The Journal of antimicrobial chemotherapy.

[48]  Dong Wook Lee,et al.  Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial , 2015, Journal of gastroenterology and hepatology.

[49]  M. Ochagavía,et al.  First-line eradication rates comparing two shortened non-bismuth quadruple regimens against Helicobacter pylori: an open-label, randomized, multicentre clinical trial. , 2015, The Journal of antimicrobial chemotherapy.

[50]  H. Fakheri,et al.  Comparison Between 10‐ and 14‐Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial , 2015, Helicobacter.

[51]  F. Rivas-Ruíz,et al.  Prevalence of Primary Resistance of Helicobacter pylori to Clarithromycin and Levofloxacin in Southern Spain , 2015, Digestion.

[52]  P. Malfertheiner,et al.  Kyoto global consensus report on Helicobacter pylori gastritis , 2015, Gut.

[53]  X. Liang,et al.  Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial , 2015, Scandinavian journal of gastroenterology.

[54]  E. Pérez-Trallero,et al.  Helicobacter pylori Infection in Children. Antimicrobial Resistance and Treatment Response , 2015, Helicobacter.

[55]  D. Graham,et al.  Letter: bismuth, levofloxacin, amoxicillin, PPI quadruple therapy is not an effective first or second line regimen in the presence of levofloxacin resistance , 2015, Alimentary pharmacology & therapeutics.

[56]  Hsiu‐Po Wang,et al.  The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors—A Nationwide Study , 2015, PloS one.

[57]  D. S̆timac,et al.  Probiotics for Standard Triple Helicobacter pylori Eradication , 2015, Medicine.

[58]  Yan Li,et al.  Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. , 2015, International journal of clinical and experimental medicine.

[59]  Wei Qian,et al.  Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. , 2015, World journal of gastroenterology.

[60]  J. Gisbert,et al.  Helicobacter pylori second‐line rescue therapy with levofloxacin‐ and bismuth‐containing quadruple therapy, after failure of standard triple or non‐bismuth quadruple treatments , 2015, Alimentary pharmacology & therapeutics.

[61]  C. O'Morain,et al.  Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study , 2015, Alimentary pharmacology & therapeutics.

[62]  H. Yoon,et al.  Optimal initiation of Helicobacter pylori eradication in patients with peptic ulcer bleeding. , 2015, World journal of gastroenterology.

[63]  J. Gisbert,et al.  Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[64]  J. Gisbert,et al.  Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy , 2015, Digestive Diseases and Sciences.

[65]  Yong Xie,et al.  Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis , 2015, Experimental and therapeutic medicine.

[66]  Miao Shen,et al.  Meta-analysis of the efficacy of probiotics in Helicobacter pylori eradication therapy. , 2014, World journal of gastroenterology.

[67]  A. Di Leo,et al.  Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens. , 2014, Journal of gastrointestinal and liver diseases : JGLD.

[68]  Guoxin Zhang,et al.  The Effect of Probiotics Supplementation on Helicobacter pylori Eradication Rates and Side Effects during Eradication Therapy: A Meta-Analysis , 2014, PloS one.

[69]  Harminder Singh,et al.  Canadian Association of Gastroenterology policy on the application for, and implementation of, clinical practice guidelines. , 2014, Canadian journal of gastroenterology & hepatology.

[70]  L. Bujanda,et al.  Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions , 2014, European journal of gastroenterology & hepatology.

[71]  J. Gisbert,et al.  Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. , 2014, World journal of gastroenterology.

[72]  Deng-Chyang Wu,et al.  Randomized Controlled Trial Comparing 7-Day Triple, 10-Day Sequential, and 7-Day Concomitant Therapies for Helicobacter pylori Infection , 2014, Antimicrobial Agents and Chemotherapy.

[73]  P. Malfertheiner,et al.  Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori , 2014, Alimentary pharmacology & therapeutics.

[74]  Hsiao-Yun Hu,et al.  Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients , 2014, Gut and liver.

[75]  Nayoung Kim,et al.  Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea. , 2014, World journal of gastroenterology.

[76]  Nayoung Kim,et al.  The efficacy of hybrid therapy as first‐line regimen for Helicobacter pylori infection compared with sequential therapy , 2014, Journal of gastroenterology and hepatology.

[77]  D. Graham,et al.  Feasibility of Shortening 14‐day Hybrid Therapy While Maintaining an Excellent Helicobacter pylori Eradication Rate , 2014, Helicobacter.

[78]  C. Hassan,et al.  Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study. , 2014, Journal of medical microbiology.

[79]  D. Sgouras,et al.  Su1184 A Randomised Study Comparing 10 Days Concomitant and Sequential Treatments for the Eradication of Helicobacter pylori, in a High Clarithromycin Resistance Area , 2014 .

[80]  J. Gisbert,et al.  Su1171 Second-Line Rescue Triple Therapy With Levofloxacin After Failure of Non-Bismuth Quadruple “Sequential” or “Concomitant” Treatment to Eradicate H. pylori Infection , 2014 .

[81]  Nayoung Kim,et al.  The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea , 2014, Gut and liver.

[82]  D. Graham,et al.  Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[83]  Deng-Chyang Wu,et al.  Ten‐Day Quadruple Therapy Comprising Proton‐Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin Achieves a High Eradication Rate for Helicobacter pylori Infection after Failure of Sequential Therapy , 2014, Helicobacter.

[84]  Shan Li,et al.  Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children , 2014, European Journal of Pediatrics.

[85]  J. Gisbert,et al.  Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection , 2014, Digestive Diseases and Sciences.

[86]  D. Forman,et al.  Optimum duration of regimens for Helicobacter pylori eradication. , 2013, The Cochrane database of systematic reviews.

[87]  D. But,et al.  Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial , 2013, Gut.

[88]  D. Sgouras,et al.  Clinical Evaluation of a Ten‐Day Regimen with Esomeprazole, Metronidazole, Amoxicillin, and Clarithromycin for the Eradication of Helicobacter pylori in a High Clarithromycin Resistance Area , 2013, Helicobacter.

[89]  C. Hassan,et al.  Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. , 2013, Clinics and research in hepatology and gastroenterology.

[90]  Nayoung Kim,et al.  Meta‐analysis: Is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? , 2013, Journal of gastroenterology and hepatology.

[91]  D. Graham,et al.  Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China , 2013, European journal of gastroenterology & hepatology.

[92]  D. Graham,et al.  Effect of Fluoroquinolone Resistance on 14‐day Levofloxacin Triple and Triple Plus Bismuth Quadruple Therapy , 2013, Helicobacter.

[93]  J. Gisbert,et al.  Probióticos en el tratamiento erradicador de Helicobacter pylori: sin evidencia para su uso generalizado , 2013 .

[94]  Z. Mei,et al.  Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. , 2013, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[95]  C. Scarpignato,et al.  Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy , 2013, BMJ.

[96]  Mahsa Khodadoostan,et al.  The Effects of Multistrain Probiotic Compound on Bismuth‐Containing Quadruple Therapy for Helicobacter pylori Infection: A Randomized Placebo‐Controlled Triple‐Blind Study , 2013, Helicobacter.

[97]  J. Gisbert,et al.  Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. , 2013, Gastroenterology.

[98]  P. Malfertheiner,et al.  Meta-Analysis of Bismuth Quadruple Therapy versus Clarithromycin Triple Therapy for Empiric Primary Treatment of Helicobacter pylori Infection , 2013, Digestion.

[99]  X. Liang,et al.  Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[100]  H. Jung,et al.  Clinical Outcomes of Two‐Week Sequential and Concomitant Therapies for Helicobacter pylori Eradication: A Randomized Pilot Study , 2013, Helicobacter.

[101]  J. Gisbert,et al.  [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. , 2013, Gastroenterologia y hepatologia.

[102]  J. Gisbert,et al.  Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection , 2013, Scandinavian journal of gastroenterology.

[103]  J. Gisbert,et al.  Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice , 2013, Gut.

[104]  Z. Zeng,et al.  Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection , 2013, Journal of digestive diseases.

[105]  F. Bermejo,et al.  [III Spanish Consensus Conference on Helicobacter pylori infection]. , 2013, Gastroenterologia y hepatologia.

[106]  J. Gisbert,et al.  A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication) , 2013, Expert opinion on pharmacotherapy.

[107]  H. Fakheri,et al.  Comparison of Hybrid and Sequential Therapies for Helicobacter pylori Eradication in Iran: A Prospective Randomized Trial , 2013, Helicobacter.

[108]  R. Mattar,et al.  Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study , 2013, BMC Gastroenterology.

[109]  J. Gisbert,et al.  Second-line Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection: Time Trends in a Spanish Multicenter Study of 1000 Patients , 2013, Journal of clinical gastroenterology.

[110]  Hsiu‐Po Wang,et al.  Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial , 2013, The Lancet.

[111]  Zhen-hua Wang,et al.  Meta-Analysis of the Efficacy and Safety of Lactobacillus-containing and Bifidobacterium-containing Probiotic Compound Preparation in Helicobacter pylori Eradication Therapy , 2013, Journal of clinical gastroenterology.

[112]  B. Marshall,et al.  Helicobacter pylori eradication in Western Australia using novel quadruple therapy combinations , 2012, Alimentary pharmacology & therapeutics.

[113]  S. Valabrega,et al.  Helicobacter pylori eradication: sequential therapy and Lactobacillus reuteri supplementation. , 2012, World journal of gastroenterology.

[114]  A. Gasbarrini,et al.  Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. , 2012, World journal of gastroenterology.

[115]  D. Graham,et al.  Greater Than 95% Success with 14‐day Bismuth Quadruple Anti‐ Helicobacter pylori Therapy: A Pilot Study in US Hispanics , 2012, Helicobacter.

[116]  Deng-Chyang Wu,et al.  The Efficacy of Second‐Line Anti‐Helicobacter pylori Therapy Using an Extended 14‐Day Levofloxacin/Amoxicillin/Proton‐Pump Inhibitor Treatment – A Pilot Study , 2012, Helicobacter.

[117]  R. Francavilla,et al.  Probiotics and Helicobacter pylori infection , 2012 .

[118]  J. Gisbert,et al.  Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin‐Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin‐Resistant Strains , 2012, Helicobacter.

[119]  R. Vilaichone,et al.  Pilot Studies to Identify the Optimum Duration of Concomitant Helicobacter pylori Eradication Therapy in Thailand , 2012, Helicobacter.

[120]  G. de’Angelis,et al.  Helicobacter pylori Infection: Sequential Therapy Followed by Levofloxacin‐Containing Triple Therapy provides a Good Cumulative Eradication Rate , 2012, Helicobacter.

[121]  H. Fakheri,et al.  A modified Bismuth‐Containing Quadruple Therapy Including a Short Course of Furazolidone for Helicobacter pylori Eradication After Sequential Therapy Failure , 2012, Helicobacter.

[122]  J. Gisbert,et al.  Long-Term Follow-Up of 1,000 Patients Cured of Helicobacter pylori Infection Following an Episode of Peptic Ulcer Bleeding , 2012, The American Journal of Gastroenterology.

[123]  K. Higuchi,et al.  Strategies for peptic ulcer healing after 1 week proton pump inhibitor-based triple Helicobacter pylori eradication therapy in Japanese patients: differences of gastric ulcers and duodenal ulcers , 2012, Journal of clinical biochemistry and nutrition.

[124]  J. Gisbert.  Letter: third‐line rescue therapy with levofloxacin after failure of two treatments to eradicate Helicobacter pylori infection , 2012, Alimentary pharmacology & therapeutics.

[125]  H. Goossens,et al.  Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption , 2012, Gut.

[126]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[127]  X. Calvet,et al.  Fourth‐line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures , 2012, Alimentary pharmacology & therapeutics.

[128]  J. Gisbert,et al.  Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori , 2012, Clinical and experimental gastroenterology.

[129]  K. Sakamoto,et al.  Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan. , 2012, World journal of gastrointestinal pharmacology and therapeutics.

[130]  F. Mégraud.  The challenge of Helicobacter pylori resistance to antibiotics: the comeback of bismuth-based quadruple therapy , 2012, Therapeutic advances in gastroenterology.

[131]  J. Gisbert,et al.  Review article: rifabutin in the treatment of refractory Helicobacter pylori infection , 2012, Alimentary pharmacology & therapeutics.

[132]  J. Gisbert,et al.  Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough , 2011, Alimentary pharmacology & therapeutics.

[133]  J. Gisbert,et al.  Review article: non‐bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori , 2011, Alimentary pharmacology & therapeutics.

[134]  D. Graham,et al.  Twice‐a‐Day Bismuth‐Containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Trial of 10 and 14 Days , 2011, Helicobacter.

[135]  Z. Polat,et al.  A New Modified Concomitant Therapy for Helicobacter pylori Eradication in Turkey , 2011, Helicobacter.

[136]  D. Graham,et al.  Modified Sequential Helicobacter pylori Therapy: Proton Pump Inhibitor and Amoxicillin for 14 Days with Clarithromycin and Metronidazole added as a Quadruple (Hybrid) Therapy for the Final 7 Days , 2011, Helicobacter.

[137]  P. Malfertheiner,et al.  Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial , 2011, The Lancet.

[138]  J. Gisbert.  Tratamientos de rescate ante el fracaso erradicador de Helicobacter pylori , 2011 .

[139]  H. Szajewska,et al.  Meta‐analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment , 2010, Alimentary pharmacology & therapeutics.

[140]  P. Malfertheiner.  Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication , 2010, Nature Reviews Gastroenterology &Hepatology.

[141]  F. Liu,et al.  Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. , 2010, World journal of gastroenterology.

[142]  D. Graham,et al.  Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. , 2010, Gastroenterology clinics of North America.

[143]  S. Pontone,et al.  Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[144]  Guoxin Zhang,et al.  Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis , 2010, Wiener klinische Wochenschrift.

[145]  C. Hassan,et al.  Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. , 2010, Journal of gastrointestinal and liver diseases : JGLD.

[146]  F. Mégraud,et al.  Sequential Therapy for Helicobacter pylori Eradication: A Critical Review , 2010, Journal of clinical gastroenterology.

[147]  D. Haldane,et al.  Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection. , 2010, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[148]  D. J. Kim,et al.  T1019 Efficacy of the 14-Day Quadruple Regimen (Proton Pump Inhibitor, Bismuth, Tetracycline and Metronidazole) as a Rescue Therapy After Failure With the 10-Days Sequential Therapy for Eradication of Helicobacter pylori , 2010 .

[149]  J. Gisbert,et al.  Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[150]  Z. Polat,et al.  Comparison of 7- and 14-day first-line therapies including levofloxacin in patients with Helicobacter pylori positive non-ulcer dyspepsia. , 2010, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[151]  P. Moayyedi,et al.  Empiric Quadruple vs. Triple Therapy for Primary Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability , 2010, The American Journal of Gastroenterology.

[152]  A. Gasbarrini,et al.  Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication. , 2009, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[153]  K. Murakami,et al.  Sitafloxacin Activity against Helicobacter pylori Isolates, Including Those with gyrA Mutations , 2009, Antimicrobial Agents and Chemotherapy.

[154]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[155]  J. Nagpal,et al.  Meta‐analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication , 2009, Alimentary pharmacology & therapeutics.

[156]  J. Zou,et al.  Meta‐Analysis: The Effect of Supplementation with Lactoferrin on Eradication Rates and Adverse Events During Helicobacter pylori Eradication Therapy , 2009, Helicobacter.

[157]  J. Nagpal,et al.  Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials , 2009, European journal of gastroenterology & hepatology.

[158]  T. Rokkas,et al.  Cumulative H. pylori Eradication Rates in Clinical Practice by Adopting First and Second-Line Regimens Proposed by the Maastricht III Consensus and a Third-Line Empirical Regimen , 2008, The American Journal of Gastroenterology.

[159]  Deng-Chyang Wu,et al.  Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures , 2008, European journal of clinical investigation.

[160]  P. Malfertheiner,et al.  Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients , 2008, European journal of gastroenterology & hepatology.

[161]  J. Gisbert,et al.  ¿Cómo localizar, elaborar, evaluar y utilizar guías de práctica clínica? , 2008 .

[162]  M. Stolte,et al.  One‐Week Once‐Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent Helicobacter pylori Resistant to Both Metronidazole and Clarithromycin , 2008, Helicobacter.

[163]  D. van der Poorten,et al.  The effectiveness of rifabutin triple therapy for patients with difficult‐to‐eradicate Helicobacter pylori in clinical practice , 2007, Alimentary pharmacology & therapeutics.

[164]  J. Gisbert,et al.  Empirical rescue therapy after Helicobacter pylori treatment failure: a 10‐year single‐centre study of 500 patients , 2007, Alimentary pharmacology & therapeutics.

[165]  C. Hassan,et al.  Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[166]  K. Chu,et al.  Clinical trial: levofloxacin‐based quadruple therapy was inferior to traditional quadruple therapy in the treatment of resistant Helicobacter pylori infection , 2007, Alimentary pharmacology & therapeutics.

[167]  L. Fischbach,et al.  Meta‐analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first‐line therapies for Helicobacter pylori , 2007, Alimentary pharmacology & therapeutics.

[168]  J. Wu,et al.  Levofloxacin‐Containing Triple Therapy to Eradicate the Persistent H. pylori after a Failed Conventional Triple Therapy , 2007, Helicobacter.

[169]  I. Subei,et al.  One Week of Esomeprazole Triple Therapy vs. 1 Week of Omeprazole Triple Therapy Plus 3 Weeks of Omeprazole for Duodenal Ulcer Healding in Helicobacter pylori-Positive Patients , 2007, Digestive Diseases and Sciences.

[170]  T Rokkas,et al.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report , 2006, Gut.

[171]  R. Moreno-otero,et al.  Third‐line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures , 2006, Alimentary pharmacology & therapeutics.

[172]  J. Tong,et al.  Meta‐analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy , 2006, Alimentary pharmacology & therapeutics.

[173]  W. Chey,et al.  Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent Helicobacter pylori Infection: A Meta-Analysis , 2006, The American Journal of Gastroenterology.

[174]  C. Hassan,et al.  Second-line treatment for Helicobacter pylori eradication after sequential therapy failure: a pilot study , 2006 .

[175]  J. Gisbert,et al.  Third-Line Rescue Therapy with Levofloxacin After Two H. pylori Treatment Failures , 2006, The American Journal of Gastroenterology.

[176]  J. Gisbert,et al.  Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure , 2006, Alimentary pharmacology & therapeutics.

[177]  Sumio Watanabe,et al.  Tetracycline, metronidazole and amoxicillin‐metronidazole combinations in proton pump inhibitor‐based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection , 2006, Journal of gastroenterology and hepatology.

[178]  J. Gisbert,et al.  Helicobacter pylori first‐line treatment and rescue options in patients allergic to penicillin , 2005, Alimentary pharmacology & therapeutics.

[179]  J. Gisbert,et al.  Helicobacter pylori“Rescue” Therapy After Failure of Two Eradication Treatments , 2005, Helicobacter.

[180]  J. Gisbert,et al.  [Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference]. , 2005, Medicina clinica.

[181]  C. Hassan,et al.  A 10‐day levofloxacin‐based triple therapy in patients who have failed two eradication courses , 2005, Alimentary pharmacology & therapeutics.

[182]  J. Gisbert,et al.  Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference. , 2005, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[183]  J. Rodríguez-Orengo,et al.  High Eradication Rates of Helicobacter pylori Infection with First- and Second-Line Combination of Esomeprazole, Tetracycline, and Metronidazole in Patients Allergic to Penicillin , 2005, Digestive Diseases and Sciences.

[184]  J. Gisbert,et al.  Systematic review and meta‐analysis: is 1‐week proton pump inhibitor‐based triple therapy sufficient to heal peptic ulcer? , 2005, Alimentary pharmacology & therapeutics.

[185]  L. Fischbach,et al.  Meta‐analysis: the efficacy, adverse events, and adherence related to first‐line anti‐Helicobacter pylori quadruple therapies , 2004, Alimentary pharmacology & therapeutics.

[186]  G. Guyatt,et al.  Grading quality of evidence and strength of recommendations , 2004, BMJ : British Medical Journal.

[187]  J. Gisbert,et al.  Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy (with or without long‐term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer , 2004 .

[188]  J. Gisbert,et al.  Helicobacter pylori eradication therapy vs. antisecretory non‐eradication therapy for the prevention of recurrent bleeding from peptic ulcer , 2004 .

[189]  M. Färkkilä,et al.  Eradication of Helicobacter pylori improves the healing rate and reduces the relapse rate of nonbleeding ulcers in patients with bleeding peptic ulcer , 2003, American Journal of Gastroenterology.

[190]  Chia‐Long Lee,et al.  Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study. , 2003, Archives of internal medicine.

[191]  Sheng-Nan Lu,et al.  One-week low-dose triple therapy without anti-acid treatment has sufficient efficacy on Helicobacter pylori eradication and ulcer healing. , 2003, Hepato-gastroenterology.

[192]  X. Calvet,et al.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis , 2003, Alimentary pharmacology & therapeutics.

[193]  J. Gisbert,et al.  Triple vs. quadruple therapy for treating Helicobacter pylori infection: an updated meta‐analysis , 2003, Alimentary pharmacology & therapeutics.

[194]  R. Hunt,et al.  Bismuth-Based Quadruple Therapy Using a Single Capsule of Bismuth Biskalcitrate, Metronidazole, and Tetracycline Given With Omeprazole Versus Omeprazole, Amoxicillin, and Clarithromycin for Eradication of Helicobacter pylori in Duodenal Ulcer Patients: A Prospective, Randomized, Multicenter, North A , 2003, American Journal of Gastroenterology.

[195]  J. Gisbert,et al.  Helicobacter pylori and Bleeding Peptic Ulcer: What is the Prevalence of the Infection in Patients with this Complication? , 2003, Scandinavian journal of gastroenterology.

[196]  K. Tominaga,et al.  Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study , 2003, Alimentary pharmacology & therapeutics.

[197]  R. Colin.  Duodenal ulcer healing with 1‐week eradication triple therapy followed, or not, by anti‐secretory treatment: a multicentre double‐blind placebo‐controlled trial , 2002, Alimentary pharmacology & therapeutics.

[198]  P. Malfertheiner,et al.  Current concepts in the management of Helicobacter pylori infection—The Maastricht 2‐2000 Consensus Report , 2002, Alimentary pharmacology & therapeutics.

[199]  U. Klotz,et al.  Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). , 2002, Archives of internal medicine.

[200]  P. Malfertheiner,et al.  A meta‐analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori‐associated gastric or duodenal ulcer , 2001, Alimentary pharmacology & therapeutics.

[201]  Z. Tulassay,et al.  One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease , 2001, European journal of gastroenterology & hepatology.

[202]  M. Gubina,et al.  Is a one‐week course of triple anti‐Helicobacter pylori therapy sufficient to control active duodenal ulcer? , 2001, Alimentary pharmacology & therapeutics.

[203]  G. Capurso,et al.  Occurrence and relapse of bleeding from duodenal ulcer: respective roles of acid secretion and Helicobacter pylori infection , 2001, Alimentary pharmacology & therapeutics.

[204]  M. Rizzetto,et al.  The Effect of the Eradication of Helicobacter pylori Infection on Hemorrhage Because of Duodenal Ulcer , 2001, Journal of clinical gastroenterology.

[205]  J. Gisbert,et al.  Resistencia de Helicobacter pylori al metronidazol y a la claritromicina en España. Una revisión sistemática , 2001 .

[206]  A. Gasbarrini,et al.  Rifabutin‐based Helicobacter pylori eradication ‘rescue therapy’ , 2001, Alimentary pharmacology & therapeutics.

[207]  N. Lehn,et al.  Rifabutin-based Triple Therapy After Failure of Helicobacter pylori Eradication Treatment: Preliminary Experience , 2000, Journal of clinical gastroenterology.

[208]  J. Gisbert,et al.  Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta‐analysis of eradication of Helicobacter pylori , 2000, Alimentary pharmacology & therapeutics.

[209]  W. Wong,et al.  Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage— a long-term randomized, controlled study , 2000, American Journal of Gastroenterology.

[210]  K. Lai,et al.  Ulcer‐healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage , 2000, Alimentary pharmacology & therapeutics.

[211]  N. Borruel,et al.  Helicobacter pylori eradication prevents recurrence from peptic ulcer haemorrhage , 2000, European journal of gastroenterology & hepatology.

[212]  Clemente,et al.  Rifabutin‐based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens , 2000, Alimentary pharmacology & therapeutics.

[213]  J. Gisbert,et al.  [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. , 1999, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[214]  J. Gisbert,et al.  Helicobacter pylori y hemorragia digestiva por úlcera duodenal: prevalencia de la infección, eficacia de tres terapias triples y papel de la erradicación en la prevención de la recidiva hemorrágica , 1999 .

[215]  N. Okabe,et al.  A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate , 1998, Journal of Gastroenterology.

[216]  J. Lambert,et al.  The impact of Helicobacter pylori eradication on peptic ulcer healing , 1998, American Journal of Gastroenterology.

[217]  S. Milani,et al.  Eradication of helicobacter pylori reduces the rate of duodenal ulcer rebleeding: a long-term follow-up study , 1998, American Journal of Gastroenterology.

[218]  U. Klotz,et al.  Amoxicillin/Metronidazole/Omeprazole/Clarithromycin: A New, Short Quadruple Therapy for Helicobacter pylori Eradication , 1998, Helicobacter.

[219]  F. Chan,et al.  One-Week Antibiotics versus Maintenance Acid Suppression Therapy for Helicobacter pylori-Associated Peptic Ulcer Bleeding , 1997, Digestive Diseases and Sciences.

[220]  D. Schilling,et al.  Cure with omeprazole plus amoxicillin versus long-term ranitidine therapy in Helicobacter pylori-associated peptic ulcer bleeding. , 1997, Gastrointestinal endoscopy.

[221]  J. Gisbert,et al.  [Helicobacter pylori and duodenal ulcer: a causal relation or mere association?]. , 1997, Revista clinica espanola.

[222]  J. Labenz,et al.  One‐week low‐dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers , 1997, Alimentary pharmacology & therapeutics.

[223]  J. Pajares,et al.  Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. , 1996, The American journal of gastroenterology.

[224]  D. Jaspersen,et al.  Omeprazole-amoxycillin therapy for eradication ofHelicobacter pylori in duodenal ulcer bleeding: Preliminary results of a pilot study , 1995, Journal of Gastroenterology.

[225]  D. Graham,et al.  Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. , 1993, Scandinavian journal of gastroenterology.

[226]  Norman Crolee Dalkey,et al.  An experimental study of group opinion , 1969 .

[227]  Sandra Agudo-Fernández,et al.  Retrospective analysis of the use of quadruple therapy with bismuth (Pylera®) in real-life clinical practice in Spain. , 2018, Gastroenterology & hepatology.

[228]  M. Romero Gómez,et al.  A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients. , 2017, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[229]  M. Kutz,et al.  [Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]. , 2016, Medicina clínica (Ed. impresa).

[230]  R. Vilaichone,et al.  Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[231]  Hiroshi Watanabe,et al.  Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin. , 2014, Internal medicine.

[232]  J. Gisbert,et al.  Probiotics for Helicobacter pylori eradication therapy: not ready for prime time. , 2013, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[233]  J. Gisbert,et al.  [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. , 2013, Gastroenterologia y hepatologia.

[234]  G. Qirjako,et al.  The efficacy of levofloxacin-based triple therapy for first-line helicobacter pylori eradication. , 2013, Medical archives.

[235]  J. Gisbert,et al.  [III Spanish Consensus Conference on Helicobacter pylori infection]. , 2013, Gastroenterologia y hepatologia.

[236]  M. Pereira,et al.  The use of probiotics in Helicobacter pylori eradication therapy. , 2013, Journal of clinical gastroenterology.

[237]  J. Llorca,et al.  Antimicrobial susceptibility of Helicobacter pylori to six antibiotics currently used in Spain. , 2012, The Journal of antimicrobial chemotherapy.

[238]  D. Graham,et al.  Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[239]  M. Marušić,et al.  High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial , 2007, Wiener klinische Wochenschrift.

[240]  B. Dmitrović,et al.  The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer. , 2005, Collegium antropologicum.

[241]  L. Marzio,et al.  Triple therapy for 7 days vs. triple therapy for 7 days plus omeprazole for 21 days in treatment of active duodenal ulcer with Helicobacter pylori infection. A double blind placebo controlled trial. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[242]  J. Gisbert,et al.  Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la II Conferencia Española de Consenso , 2000 .

[243]  J. Gisbert,et al.  [Helicobacter pylori and digestive hemorrhage due to duodenal ulcer: the prevalence of the infection, the efficacy of 3 triple therapies and the role of eradication in preventing a hemorrhagic recurrence]. , 1999, Medicina clinica.

[244]  M. Amendola,et al.  [Absence of bleeding recurrence of peptic ulcer after long term follow-up of successful eradication of Helicobacter pylori]. , 1999, Acta gastroenterologica Latinoamericana.

[245]  D. Forman,et al.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group. , 1997, Gut.

[246]  F. Kozjek,et al.  Comparative amoxicillin - azithromycin treatment of Helicobacter pylori positive patients with bleeding duodenal ulcer , 1997 .

[247]  A. Karameris,et al.  Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. , 1995, Gastrointestinal endoscopy.

[248]  D. Jaspersen,et al.  Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. , 1995, Gastrointestinal endoscopy.

[249]  J. Labenz,et al.  Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. , 1994, Digestion.